Gelonghui, June 12 丨 Huaan Securities research report on the 11th pointed out that Da Rentang (600329.SH) is a century-old Chinese pharmaceutical company that has taken a new lease of life after the mixed reform. The company's products cover a wide range of products, mainly the traditional Chinese medicine business, and also the chemical medicine business. The main product, quick-acting heart saving pills, is well known and sold widely. The company relies on the main product “quick-acting heart saving pills” to build a cardiovascular product line. In recent years, the incidence and death rate of cardiovascular and cerebrovascular diseases in China has continued to increase, and demand for cardiovascular related drugs has continued to increase. In addition, the company has comprehensively promoted the new “three cores and nine wings” and “1+5” layouts, secondary development of key products, and continued scientific research and innovation. Da Ren Tang has a history of 100 years. It completed mixed reform in 2020, and proposed and promoted new “three cores and nine wings” and “1+5” strategic plans. The company has a well-known product “quick-acting heart saving pill” and has established a cardiovascular product line. As the company's strategic layout progresses, future performance has potential for development. First coverage, giving a “buy” investment rating.